Sociedad Americana de Hirudoterapia

P02 A single-centre, retrospective study of paediatric tinea capitis in the United Kingdom

Research article published in The British journal of dermatology (2025)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Research reportEnsayos clínicosHerd et al. · The British journal of dermatology, 2025

Abstract

BACKGROUND: The clinical and microbiological spectrum of paediatric tinea capitis in the United Kingdom has not been recently reported. This study evaluates recent changes in the incidence, clinical presentation, and microbiological spectrum of paediatric tinea capitis over the past nine years. METHODS: A single-centre retrospective cohort study was undertaken, including all patients under 18 years of age with microbiologically confirmed tinea capitis during two three-year periods: 2016-19 and 2022-25. Clinical records were reviewed to assess age, sex, clinical presentation, microbiological findings, and patient-reported source of transmission. RESULTS: A total of 102 patients were identified: 32 from 2016-19 and 70 from 2022-25 representing a 119% increase in cases. The proportion of patients presenting with kerion also rose considerably, from 18.8% (6/32) in 2016-19 to 35.7% (25/70) in 2022-25. Whilst Trichophyton tonsurans remained the predominant organism in both cohorts (72.4% versus 74.2% of cultured organisms), Trichophyton mentagrophytes emerged as the second most commonly isolated organism in 2022-25 (n = 6, 9.1%), having been absent in 2016-19. Patient-reported barber-associated transmission was present only in 2022-25 (n = 22). This group were exclusively male patients, with higher mean age (9.8 years) and a higher frequency of kerion (40.9%) compared to the overall study group. CONCLUSION: The incidence of paediatric tinea capitis has more than doubled in our centre, alongside a disproportionate rise in kerion presentations. The emergence of Trichophyton mentagrophytes represents a notable microbiological shift of current public health interest. The rise in suspected barber-associated transmission highlights a need for targeted prevention and education to reduce infection spread.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal Article
Indexed MeSH termsHumansTinea CapitisRetrospective StudiesChildMaleFemaleUnited KingdomChild, PreschoolAdolescentIncidenceInfantTrichophyton

Resumen

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Por qué esto importa para la hirudoterapia

Este estudio de cohorte retrospectivo de un único centro en el Reino Unido revisó a 102 niños con tinea capitis confirmada microbiológicamente entre 2016-19 y 2022-25, informando un aumento del 119% en los casos, un incremento en las presentaciones de querión (del 18.8% al 35.7%), la aparición de Trichophyton mentagrophytes como el segundo organismo más común y 22 casos de sospecha de transmisión asociada a barberos, todos en pacientes masculinos. El estudio se refiere a una infección fúngica del cuero cabelludo y su microbiología de dermatofitos; no examina sanguijuelas, el secretoma de la sanguijuela medicinal, la anticoagulación ni ninguna aplicación de hirudoterapia, por lo que no tiene relación directa con el panorama de evidencia de la ASH. Marcamos este registro como fuera de tema para la biblioteca de hirudoterapia: al ser un estudio retrospectivo de un solo centro, tampoco puede establecer causalidad ni generalizarse más allá de una sola población de captación.

Citación

P02 A single-centre, retrospective study of paediatric tinea capitis in the United Kingdom.

Herd et al. · The British journal of dermatology, 2025

Contexto clínico relacionado

Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.